PFCS
TCRX icon

Pale Fire Capital SE’s TScan Therapeutics TCRX Stock Holding History

Pale Fire Capital SE’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-47,734
Closed -$65.9K – 71
2025
Q1 		$65.9K Buy
47,734
+4,011
+9% +$8.68K 0.01% 57
2024
Q4 		$133K Hold
43,723
– – 0.03% 39
2024
Q3 		$218K Buy
43,723
+22,150
+103% +$134K 0.03% 40
2024
Q2 		$126K Hold
21,573
– – 0.01% 34
2024
Q1 		$171K Hold
21,573
– – 0.02% 36
2023
Q4 		$126K Buy
21,573
+4,998
+30% +$22.9K 0.02% 59
2023
Q3 		$42.4K Buy
+16,575
New +$38.7K ﹤0.01% 69

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Pale Fire Capital SE's TCRX Position: Q2 2025 in Review

Pale Fire Capital SE sold out of TScan Therapeutics (TCRX) in Q2 2025, closing a stake of 47,734 shares — an estimated $65.9K sold.

Pale Fire Capital SE first reported a position in TCRX in Q3 2023 and held it in 7 quarters. The position peaked at $218K in Q3 2024. 81 funds tracked by Wall St. Rank hold TCRX as of Q2 2025.

  • Pale Fire Capital SE reported no remaining TScan Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Pale Fire Capital SE sold 47,734 TScan Therapeutics shares in Q2 2025, an estimated $65.9K.
  • Pale Fire Capital SE first reported a position in TScan Therapeutics in Q3 2023 and held it in 7 quarters.
  • Pale Fire Capital SE's TScan Therapeutics position peaked at $218K in Q3 2024.
  • 81 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2025.

Based on Pale Fire Capital SE's 13F filing for Q2 2025, filed 13 Aug 2025.